Twenty years ago, Columbia scientists created a way to make neurons in a dish, a discovery that has led to clinical trials of an experimental drug that may slow the progression of ALS.
Using EEG to identify covert consciousness in unresponsive brain-injured patients could help predict which ones may recover, find researchers at Columbia and NewYork-Presbyterian.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
In an article in Scientific American’s “Talking Back Blog” published yesterday, writer Gary Stix highlights the work of Columbia’s Dr. Olajide Williams.
Ottavio Arancio, MD, PhD, of CUMC's Taub Institute, coauthored a paper on a compound that prevents memory loss in a mouse model of Alzheimer's. See Northwestern's news release: http://bit.ly/14Zqwwn
One in 4 stroke survivors suffer from PTSD symptoms within the 1st year post-event, and 1 in 9 experience chronic PTSD more than a year later - results of a study led by Columbia University Medical Center researchers.
Columbia University study looks at the relationship between families with exceptional longevity and cognitive impairment consistent with Alzheimer's disease.
Four research centers including the Center for Stroke Disparities Solutions—a partnership of the New York University Langone Medical Center and Columbia University Medical Center —will develop high-impact culturally tailored interventions aimed at lowering stroke risk among racial and ethnic minorities in the United States.
African-Americans carrying a variant in a cholesterol-processing gene, ABCA7, have double the risk for Alzheimer’s than non-carriers. A new study led by CUMC's Richard Mayeux; first author Christiane Reitz.